Building a blood biomarker panel to track ALS and detect it earlier
Studies blood samples and medical data from adults with ALS to find biomarkers.
Plain-language title generated from the registry record
Registry title: Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Key facts
- Where
- Barcelona, SpainSee the site
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Montpellier
- Trial code
- NCT07737977
- Record updated
- 30 July 2026
- Original description
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.Read full original descriptionShow less
Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.
Inclusion: Age greater than 18 years; Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria; Sporadic or familial ALS cases; Spinal-onset or bulbar-onset ALS cases.
Exclusion: Refusal to participate; Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization; Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8); Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1); Individuals participating in another research study with an ongoing exclusion period (Article L1121-12).